Related Experiment Videos
[Sulfidopeptide leukotrienes and asthma].
A T Dinh Xuan1, C Peiffer, J Marsac
1Département de Pneumologie et d'Asthmologie, Hôpital Cochin, Paris.
Revue Des Maladies Respiratoires
|January 1, 1989
Summary
Sulfidopeptide leukotrienes (s-LT) contribute to asthma by constricting airways and increasing inflammation. While anti-leukotriene drugs show promise, their long-term efficacy in asthma treatment requires further investigation.
Area of Science:
- Biochemistry
- Pulmonology
- Pharmacology
Background:
- Sulfidopeptide leukotrienes (s-LT), derived from arachidonic acid, are implicated in asthma pathophysiology.
- Their precise role, alone or with other mediators, remains under investigation.
Purpose of the Study:
- To review the role of s-LT in asthma.
- To evaluate the efficacy of anti-leukotriene therapies.
Main Methods:
- Literature review of studies on s-LT and asthma.
- Analysis of clinical trial data for anti-leukotriene drugs.
Main Results:
- s-LT constrict bronchial smooth muscle and increase airway obstruction, edema, and mucus secretion.
- These mediators also enhance non-specific bronchial hyper-responsiveness.
- Anti-leukotriene drugs generally antagonize exogenous s-LT but show variable efficacy against other stimuli.
Conclusions:
- s-LT play a significant role in asthma exacerbations.
- The long-term therapeutic contribution of anti-leukotriene agents in asthma management is yet to be fully established.